The reiteration of an Outperform rating by a reputable analyst like David Nierengarten suggests a strong vote of confidence in Inozyme Pharma's prospects. Maintaining a $15 price target indicates that the analyst believes the stock has significant upside potential from its current level. This positive endorsement is likely to influence investor sentiment and could lead to a short-term increase in the stock price.